Novel predictive biomarkers of response to immune checkpoint blockade with nivolumab ± ipilimumab in the TITAN-RCC phase 2 trial.

被引：0
|
作者：
Grimm, Marc-Oliver
Kesselmeier, Miriam
Leucht, Katharina
Schumacher, Ulrike
Tunger, Antje
Rober, Nadja
Conrad, Karsten
Sommer, Ulrich
Baretton, Gustavo Bruno
Scherag, Andre
Albiges, Laurence
Esteban, Emilio
Barthelemy, Philippe
Schmidinger, Manuela
Busch, Jonas
Perez-Valderrama, Begona
de Velasco, Guillermo
Duran, Ignacio
Schmitz, Marc
Wehner, Rebekka
机构：
[1] Jena Univ Hosp, Dept Urol, Jena, Germany
[2] Jena Univ Hosp, Inst Med Stat Comp & Data Sci, Jena, Germany
[3] Jena Univ Hosp, Ctr Clin Studies, Jena, Germany
[4] Tech Univ Dresden, Fac Med Carl Gustav Carus, Inst Immunol, Dresden, Germany
[5] Univ Hosp Carl Gustav Carus, Inst Pathol, Dresden, Germany
[6] Univ Paris Sud, Gustave Roussy Canc Campus, Dept Canc Med, Villejuif, France
[7] Hosp Univ Cent Asturias, Dept Med Oncol, Oviedo, Spain
[8] Inst Cancerol Strasbourg Europe, Dept Med Oncol, Strasbourg, France
[9] Med Univ Wien, Vienna Gen Hosp AKH, Dept Internal Med 1, Vienna, Austria
[10] Univ Hosp Charite Berlin, Dept Urol, Berlin, Germany
[11] Hosp Univ Virgen Rocio, Dept Med Oncol, Seville, Spain
[12] Hosp 12 Octubre, Dept Oncol, Madrid, Spain
[13] Hosp Univ Marques Valdecilla, Dept Med Oncol, Santander, Spain
[14] Tech Univ Dresden, Fac Med Carl Gustav Carus, Dept Immunol, Dresden, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.367
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
367
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Bioluma: Biomarkers for nivolumab and evaluation of nivolumab plus ipilimumab in lung cancer - A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response to immune checkpoint inhibition
    Fischer, R. N.
    Abdulla, D.
    Michels, S.
    Nogova, L.
    Brandes, V
    Scheffler, M.
    Schaeffer, S.
    Scheel, A.
    Thurat, M.
    Vehreschild, M.
    Thomas, R.
    von Bergwelt-Baildon, M.
    Buettner, R.
    Wolf, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 92 - 93
  • [2] Reasonability of Frequent Laboratory Analyses during Therapy with Nivolumab and Nivolumab plus Ipilimumab in Patients with Advanced or Metastatic Renal Cell Carcinoma during the Phase 2 Clinical Trial TITAN-RCC
    Franke, Klara
    Foller, Susan
    Moreno, Michele Estephania Rosero
    Ali, Nalyan
    Leistritz, Lutz
    Leucht, Katharina
    Grimm, Marc-Oliver
    CANCERS, 2024, 16 (12)
  • [3] Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial
    Grimm, Marc -Oliver
    Esteban, Emilio
    Barthelemy, Philippe
    Schmidinger, Manuela
    Busch, Jonas
    Valderrama, Begona P.
    Charnley, Natalie
    Schmitz, Marc
    Schumacher, Ulrike
    Leucht, Katharina
    Foller, Susan
    Baretton, Gustavo
    Duran, Ignacio
    de Velasco, Guillermo
    Priou, Frank
    Maroto, Pablo
    Albiges, Laurence
    LANCET ONCOLOGY, 2023, 24 (11): : 1252 - 1265
  • [4] A Phase II Study of Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS)
    Morita, Kiyomi
    Kantarjian, Hagop M.
    Bravo, Guillermo Montalban
    Sasaki, Koji
    Daver, Naval
    Jabbour, Elias
    Alvarado, Yesid
    Chien, Kelly S.
    DiNardo, Courtney D.
    Ravandi, Farhad
    Borthakur, Gautam
    Bose, Prithviraj
    Pemmaraju, Naveen
    Naqvi, Kiran
    Cortes, Jorge E.
    Kadia, Tapan M.
    Konopleva, Marina
    Rausch, Caitlin R.
    Gasior, Yvonne
    Garcia-Manero, Guillermo
    BLOOD, 2020, 136
  • [5] Dual immune checkpoint blockade in advanced well-differentiated neuroendocrine tumors, a phase II clinical trial.
    Scott, Susan Combs
    De Jesus-Acosta, Ana
    Hu, Chen
    Levy, Benjamin Philip
    Anagnostou, Valsamo
    Brahmer, Julie R.
    Illei, Peter Bela
    Jaffee, Elizabeth M.
    Marrone, Kristen
    Forde, Patrick M.
    Hann, Christine L.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response - results from the NSCLC cohort
    Fischer, R. N.
    George, J.
    Scheel, A.
    Schloesser, H.
    Brossart, P.
    Engel-Riedel, W.
    Griesinger, F.
    Grohe, C.
    Kern, J. K.
    Panse, J.
    Sebastian, M.
    Serke, M.
    Wiewrodt, R.
    Michels, S.
    Nogova, L.
    Riedel, R.
    Weber, J-P.
    Buettner, R.
    Thomas, R.
    Wolf, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1025 - S1025
  • [7] PREDICTIVE SOLUBLE BIOMARKERS OF IMMUNE RESPONSE TO CHECKPOINT BLOCKADE IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
    Raza, Afsheen
    Mohsen, Reyad
    Kanbour, Aladdin
    Gul, Abdul Rehman Zar
    Philip, Anite
    Vijayakumar, Suma
    Hydrose, Shereena
    Merhi, Maysaloun
    Inchakalody, Varghese
    Uddin, Shahab
    Al Homsi, Mohammed Ussama
    Dermime, Said
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A19 - A19
  • [8] Identification of a novel biomarker response in a prospective clinical trial of immune checkpoint blockade in recurrent ovarian carcinoma
    Cun, Han
    Hinchcliff, Emily M.
    Zhu, Ying
    Ferri-Borgogno, Sammy
    Cheng, Rita
    Burks, Jared K.
    Wong, Stephen T.
    Jazaeri, Amir A.
    Mok, Samuel C.
    CANCER RESEARCH, 2020, 80 (16)
  • [9] Biomarkers of response to first-line nivolumab therapy in patients with advanced renal cell carcinoma (RCC) enrolled in the HCRN GU16-260 trial.
    El Ahmar, Nourhan
    Matar, Sayed
    Jegede, Opeyemi
    Savla, Varunika
    Sheshdeh, Aseman Bagheri
    Ghandour, Fatme
    Denize, Thomas
    West, Destiny
    Choueiri, Toni K.
    Catalano, Paul J.
    Braun, David A.
    Haas, Naomi B.
    Hammers, Hans J.
    Bilen, Mehmet Asim
    Stein, Mark N.
    Sosman, Jeffrey A.
    Wu, Catherine J.
    McDermott, David F.
    Atkins, Michael B.
    Signoretti, Sabina
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response-Preliminary results from the NSCLC cohort.
    Fischer, Rieke Nila
    George, Julie
    Scheel, Andreas H.
    Schloesser, Hans Anton
    Vehreschild, Maria
    Brossart, Peter
    Engel-Riedel, Walburga
    Griesinger, Frank
    Grohe, Christian
    Kambartel, Karl-Otto
    Kern, Jens
    Hermes, Barbara
    Nachtkamp, Kathrin
    Panse, Jens Peter
    Sebastian, Martin
    Lehmann, Markus
    Wiewrodt, Rainer Gerhard
    Buettner, Reinhard
    Thomas, Roman K.
    Wolf, Juergen
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345